Evogene (NASDAQ:EVGN) Announces Quarterly Earnings Results

Evogene (NASDAQ:EVGN) released its quarterly earnings results on Thursday. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.78, Zacks reports. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same quarter in the prior year, the firm posted ($1.30) earnings per share.

Evogene Stock Down 0.6 %

Shares of EVGN stock traded down $0.01 during mid-day trading on Thursday, hitting $1.41. 27,026 shares of the company’s stock were exchanged, compared to its average volume of 89,095. The stock has a market cap of $7.54 million, a price-to-earnings ratio of -0.31 and a beta of 1.29. The stock has a 50-day simple moving average of $1.59 and a two-hundred day simple moving average of $2.09. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.00.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Evogene in a research report on Sunday. They set a “sell” rating for the company.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.